Prevalence and risk factors of Hepatitis C among individuals presenting to HIV testing centers, Hawassa city, Southern Ethiopia

Addisu Alemayehu, Yayehyirad Tassachew, Zufan Sisay and Techalew Shimelis

Abstract

Background: Hepatitis C virus (HCV), either alone or in combination with Human Immunodeficiency virus (HIV), constitutes a major public health concern. This study was conducted to describe the prevalence and risk factors for HCV infection in people with and without HIV infection.

Methods: Blood samples and data on socio-demographic and risk factors for HCV infection were collected from consecutive 400 HIV-positive and 400 HIV-negative individuals attending HIV testing centers in Hawassa city, from October to December, 2008. All sera were tested for antibody to HCV infection (anti-HCV) using enzyme linked immunosorbent assay (ELISA). Sera positive for anti-HCV were further tested for viral ribonucleic acid (RNA) levels using real-time polymerase chain reaction.

Results: The rate of anti-HCV positivity was 10.5% in the HIV-infected individuals compared with 6% in the HIV-negative group (p = 0.002). HCV-RNA was detected in 9.1% of anti-HCV positive samples and rates were comparable between HIV-infected and HIV-non-infected individuals. There was no significant difference in odds of HCV infection in participants with and without HCV risk factors in either HIV sero-group.

Conclusion: HIV infected individuals had significantly higher rate of anti-HCV although most of them showed no evidence of viraemia. Hence, while priority should be given for HIV infected patients, testing those with anti-HCV for HCV-RNA remains important.

Keywords: Prevalence, hepatitis C virus, human immunodeficiency virus, co-infection

Introduction

Hepatitis C virus (HCV) represents a major public health burden in both industrialized and developing countries. The prevalence of HCV infection is estimated to be 2.2-3.0% (130-170 million people) worldwide [1]. Region-specific estimates range from < 1.0% in Northern Europe to > 2.9% in Northern Africa, with the highest prevalence (15%-20%) reported in Egypt [2]. About 15 to 20% of HCV infections progress to potentially serious cirrhosis and end-stage liver disease [3]. Due to shared mode of transmission, co-infection of HCV and human immunodeficiency virus (HIV) has become a growing public health concern. Among the estimated 40 million individuals infected with HIV worldwide, about 4-5 million are chronically infected with HCV [4]. Prevalence and mode of transmission of each of the two viral infections are the main determinants of co-infection rate, and vary according to the geographic region. For instance, co-infection is high in patients that acquire the viruses through parenteral routes compared with those infected through sexual route [5].

In Ethiopia, a previous population-based survey had reported a moderate prevalence (2%) of HCV infection [6]. However, information is scarce regarding the rate of HIV-HCV co-infection in our setting where HIV is prevalent. This study was conducted to describe the prevalence and risk factors for HCV infection in people with and without HIV infection.
Methods

A sero-prevalence study of HCV was conducted in people with and without HIV infection attending HIV testing centers (Hawassa Referral Hospital, Hawassa Health Centre, Organization for Social Services for AIDS (OSSA), and Beth-Zeta Hospital) from October to December, 2008. These centers are located in Hawassa, the capital city of the Southern Nations, Nationalities and Peoples’ Regional State and one of the administrative regions in Ethiopia. The centers provide voluntary HIV counseling and testing services using two approaches: a client-initiated approach to serve people seeking to know their HIV status, and a provider-initiated approach which enables health care provider offer targeted medical services. Clients who are tested HIV positive are usually referred to the Hawassa Referral Hospital. Clinical and immunological assessments (CD4+ T cell count) at enrollment and at six-monthly follow-up visits identify those who are eligible for anti-retroviral therapy (ART). Those receiving ART monitor their disease status on a regular basis. Services including HIV counselling and testing, clinical and immunological assessments as well as ART are provided free of charge.

In this study, consecutive HIV-positive individuals who were at their first enrollment at the ART clinic as well as those who had been receiving ART for at least six months were recruited prospectively. Consecutive clients, who were tested HIV negative at any of the centers during the study period, were recruited for comparative purposes. The sample size was estimated using HCV prevalence rates of 4.5% and 0.8% in HIV-positive and HIV-negative subjects, respectively [7]. With 95% level of confidence and 80% power of the study, the required sample size would be 800 (400 individuals in each HIV sero-group). In both HIV sero-groups, only individuals aged 15 years and above were included. Among HIV-positive clients, those found with a CD4+ T cell counts below 50 cells/mm³ were excluded from the study due to the unreliability of HCV serological tests in a state of severe immunosuppression [8].

Counsellor nurses interviewed the study subjects using structured questionnaires on socio-demographic characteristics and risk factors of HIV infection such as history of traditional and modern medical practices, sexual practices, history of sexual transmitted infections (STIs), liver disease, and family history of liver disease. Remaining sera left from HIV testing and CD4+ T cell measurement were stored at -80°C for the purpose of HCV testing. All sera were screened at the Hawassa Referral Hospital laboratory for HCV antibody (anti-HCV) using Enzyme Linked Immunosorbent Assay (ELISA) (HUMAN anti-HCV ELISA, Germany). Sera found to be positive for anti-HCV were transferred in cold boxes to the International Clinical Laboratories in Addis Ababa where testing for viral ribonucleic acid (RNA) using real-time polymerase chain reaction (PCR) (Abbott Real-Time™ HCV) was performed. According to the manufacturer’s guidelines, the real-time PCR test has detection sensitivity of a viral load as low as 12 IU/ml of serum. All samples were tested in accordance with the manufacturer’s instructions and in duplicates to ensure reproducibility. Despite the possibility that the ELISA test introduces false positive result, we interpreted a positive anti-HCV test as HCV-exposure. Presence of HCV-RNA indicates active viral replication.

Data entry and analysis were performed using SPSS Version-16. Descriptive summary was presented in terms of mean, range, and proportions depending on the scale of the variable. Pearson’s Chi-square test was used to assess differences in proportion of anti-HCV marker between HIV-infected and HIV-non-infected individuals. The strength of association between HCV status and risk factors was measured by calculating odds ratios. A given statistical test was reported significant whenever it resulted in a p-value < 0.05.

The study was approved by the Ethics Committees of Aklilu Lemma Institute of Pathobiology, Addis Ababa University and the College of Medicine and Health Sciences, Hawassa University. All participants gave informed written consent, and doctors managed HCV-positive cases.

Results

Of the 402 HIV-positive and 404 HIV-negative individuals approached during the study period, 2 HIV-positive and 4 HIV-negative participants were excluded due to insufficient blood volume and refusal, respectively. The majority (94.7%) of HIV-infected participants were urban dwellers and married (48%) (Table 1). The mean age of HIV-infected participants was 31.7 years (range 18-70 years; SD 8.4) compared with 26.6 years (range 16-62 years; SD 7.3) in HIV- non-infected clients. The male to female ratio was 0.61 in HIV-positive and 0.9:1 in HIV-negative clients. Two-hundred (50%) HIV-infected participants were receiving ART.

The prevalence of anti-HCV in HIV-positive individuals was 10.5% compared to 6% in HIV-negative individuals (p = 0.002) (Table 2). A comparable rate of anti-HCV marker was observed in HIV-infected individuals with or without ART. HCV- RNA was detected in 6 (9.1%) of all 66 anti-HCV positive samples and viral load ranged from 31 IU/ml - 4.294 million IU/ml of serum. Rate of HCV- RNA was similar among anti-HCV-positive participants with or without HIV infection (7.1% versus 12.5%, respectively; p = 0.39), and in those HIV-infected with or without ART (5.3% versus 8.7%, respectively; p = 0.43).

The exposure of HIV-infected and HIV-non-infected participants to different risk factors for HCV infection is
summarised in Table 3. Histories of ear piercing and tooth extraction were the most frequently reported exposures in both HIV sero-groups. Among females with HIV infection, 22.5% reported having a history of abortion. Sero-prevalence rate of anti-HCV was higher in HIV-infected participants who reported having multiple sexual partners. There was no significant difference in odds of HCV infection in participants with and without HCV risk factors in either HIV sero-group (Table 3).

### Discussion

The sero-prevalence of anti-HCV was 10.5% in HIV-positive and 6% in HIV-negative individuals. None of the risk factors included in the analysis significantly increased the odds of HCV exposure. The rate of HIV-HCV co-infection in the present study was higher compared to findings in an earlier report which investigated residents of Addis Ababa (4.5%) [7]. Although we found a lower co-infection rate compared with developed nations [9,10], the magnitude of HCV in Ethiopia would become a concern as HIV is more prevalent in our settings.

Despite a weak association, we found a significant difference in rates of anti-HCV positivity between HIV-infected and HIV-non-infected individuals. In agreement, a previous report showed that HIV positive inhabitants in Addis Ababa had about five-fold rate of anti-HCV compared with HIV negative individuals [7]. However, associations between HCV and HIV infections in our settings were not as strong as those reported from industrialized countries where HIV can occur among HCV infected people exclusively [10,11].

Unlike most western countries, risk factors such as repeated transfusions, haemodialysis, or injection drug use are very rare in Ethiopia where transmission of HIV is primarily through heterosexual exposure [12]. While it remains to be fully established, rising evidences point to implications of sexual activity in HCV transmission [13]. Sexual transmission of HCV that might be facilitated by HIV and other STIs has also been reported [14,15]. Therefore, the role of sexual transmission should not be neglected as it may contribute to the higher rate of anti-HCV among HIV-infected individuals.

In the current study, the odds of HCV infection were not shown to be significantly affected by the exposure status of participants to various medical practices. This result contrasts with affording from Egypt where risk factors including blood transfusion, invasive medical procedures, and frequent injections significantly increased the odds of HCV infection [16]. This may be due to the strength of risk factors varying according to HCV epidemiology in a given geographical area. Moreover, unlike a report from Brazil [13], our investigation as well as a previous study from Egypt [16] showed that the odds of HCV infection was not significantly higher in

### Table 1 Socio-demographic characteristics of HIV-positive and HIV-negative individuals at Hawassa HIV testing centers, 2008

| Characteristics         | HIV positive (%) | HIV negative (%) | Total (%) |
|-------------------------|------------------|------------------|-----------|
| Residence               |                  |                  |           |
| Rural                   | 21 (5.3)         | 17 (4.2)         | 38 (4.8)  |
| Urban                   | 379 (94.7)       | 383 (95.8)       | 762 (95.2)|
| Sex                     |                  |                  |           |
| Male                    | 151 (37.8)       | 191 (47.8)       | 342 (42.8)|
| Female                  | 249 (62.2)       | 209 (52.2)       | 458 (57.2)|
| Age (years)             |                  |                  |           |
| <20                     | 6 (12.5)         | 42 (87.5)        | 48 (6)    |
| 20-29                   | 164 (40.5)       | 241 (59.5)       | 405 (50.6)|
| 30-39                   | 161 (63.6)       | 92 (36.4)        | 253 (31.6)|
| 40-49                   | 55 (75.3)        | 18 (24.7)        | 73 (9.1)  |
| ≥50                     | 14 (66.7)        | 7 (33.3)         | 21 (2.6)  |
| Marital status          |                  |                  |           |
| Married                 | 192 (48)         | 97 (24.2)        | 289 (36.1)|
| Single                  | 60 (15)          | 274 (68.5)       | 334 (41.8)|
| Divorced                | 60 (15)          | 20 (50)          | 80 (10)   |
| Widowed                 | 88 (22)          | 92 (2.2)         | 97 (12.1) |
| Religion                |                  |                  |           |
| Orthodox                | 250 (62.5)       | 163 (40.8)       | 413 (51.6)|
| Protestant              | 112 (28.0)       | 199 (49.8)       | 311 (38.9)|
| Muslim                  | 31 (7.8)         | 37 (9.2)         | 68 (8.5)  |
| Other                   | 7 (1.8)          | 1 (0.2)          | 8 (1.0)   |
| Educational status      |                  |                  |           |
| Illiterate              | 57 (14.2)        | 19 (48)          | 76 (9.5)  |
| Primary school          | 169 (42.2)       | 72 (18.0)        | 241 (30.1)|
| Secondary school        | 150 (37.5)       | 139 (34.8)       | 289 (36.1)|
| Diploma                 | 16 (4.0)         | 119 (29.8)       | 135 (16.9)|
| Degree                  | 8 (2)            | 51 (12.8)        | 59 (7.4)  |

### Table 2 Distribution of anti-HCV and HCV-RNA in HIV-positive and HIV-negative individuals at Hawassa HIV testing centers, 2008

| HCV Marker | Total tested | Number (%) positive | HIV-positive | ART naives | Total | HIV-negative |
|------------|--------------|---------------------|-------------|------------|-------|--------------|
|            |              |                     | Tested On ART | Tested +ve | Tested | Tested +ve |
| Anti-HCV   | 800          | 66 (8.2)            | 200         | 19 (9.5)   | 400   | 42 (10.5)   |
| HCV-RNA    | 66           | 6 (9.1)             | 19          | 1 (5.3)    | 42    | 3 (7.1)     |

Alemayehu et al. BMC Research Notes 2011, 4:193
http://www.biomedcentral.com/1756-0500/4/193
Table 3 Anti-HCV positivity in relation to HCV risk factors in HIV-positive and HIV- negative individuals at Hawassa HIV testing centers, 2008

| Characteristics                      | HIV-positive | HIV-negative |
|--------------------------------------|--------------|--------------|
|                                      | No (%) tested| No (%) tested|
|                                      | for anti-HCV | for anti-HCV |
|                                      | Crude odds   | Crude odds   |
|                                      | ratio (95% CI)| ratio (95% CI)|
| Hospital admission                   |              |              |
| No                                   | 300(75.0)    | 342 (85.5)   |
| Yes                                  | 100(25.0)    | 58 (14.5)    |
| Blood transfusion                    |              |              |
| No                                   | 388(97.0)    | 398(99.5)    |
| Yes                                  | 12(3.0)      | 2(0.5)       |
| Unsafe injection                     |              |              |
| No                                   | 375(93.8)    | 384(96.0)    |
| Yes                                  | 25(6.2)      | 16(4.0)      |
| Multiple sexual partners *           |              |              |
| No                                   | 315(78.8)    | 344(86.0)    |
| Yes                                  | 85(21.2)     | 56(14.0)     |
| Sexual transmitted infections **     |              |              |
| No                                   | 282(70.5)    | 380(95.0)    |
| Yes                                  | 118(29.5)    | 20(5.0)      |
| Tooth extraction                     |              |              |
| No                                   | 278(69.5)    | 286(71.5)    |
| Yes                                  | 122(30.5)    | 114(28.5)    |
| Catheterization                      |              |              |
| No                                   | 393(98.2)    | 399(99.8)    |
| Yes                                  | 7(1.8)       | 1(0.2)       |
| Scarification                        |              |              |
| No                                   | 373(93.2)    | 367(91.8)    |
| Yes                                  | 27(6.8)      | 33(8.2)      |
| Abortion                             |              |              |
| No                                   | 193(77.5)    | 195(93.3)    |
| Yes                                  | 56(22.5)     | 14(6.7)      |
| Ear piercing                         |              |              |
| No                                   | 240(60.0)    | 292(73.0)    |
| Yes                                  | 160(40.0)    | 108(27.0)    |
| Surgery ***                          |              |              |
| No                                   | 376(94.0)    | 388(97.0)    |
| Yes                                  | 24(6.0)      | 12(3.0)      |
| Blood letting                        |              |              |
| No                                   | 390(97.5)    | 398(99.5)    |
| Yes                                  | 10(2.5)      | 2(0.5)       |
| Tattooing                            |              |              |
| No                                   | 365(91.2)    | 376(94.0)    |
| Yes                                  | 35(8.8)      | 24(6.0)      |
| History of liver disease ****        |              |              |
| No                                   | 373(93.2)    | 387(96.8)    |
| Yes                                  | 27(6.8)      | 13(3.2)      |
| Contact with a person having liver disease |        |             |
| No                                   | 372(93.0)    | 379(94.8)    |
| Yes                                  | 28(7.0)      | 21(5.2)      |

* Having more than one sexual partner; ** have ever been diagnosed for sexual transmitted infections (excluding HIV); *** ever had minor or major surgical operation; **** have ever been diagnosed for liver disease
participants with tattoos or ear piercing compared with those without the respective risk factors in either HIV sero-groups. HCV infection commonly takes achronic course and studies have reported viraemia persisting in over 80% of infected individuals [17,18]. In the present study, however, HCV-RNA was detected in 9.1% of anti-HCV positive individuals. Such a lower rate of HCV-RNA is unusual and points to a need for further investigation in our settings to confirm or challenge this finding. Factors such as intact immune status [19] and heterosexual HCV transmission [20] were suggested to contribute to varying rates of spontaneous HCV clearance in different geographical regions. In contrast, our study lacked enough power to assess whether factors such as demographic characteristics, routes of transmission, HIV and ART status were influencing rate of HCV clearance.

Findings in this study need to be interpreted in light of its methodological limitations. First, lost participants, who tested HIV positive at the centers and did not register at the ART clinic, may introduce selection bias. Second, there could be a survival bias as a result of deaths occurring among patients with viral hepatitis C within the six months following the ART initiation. Third, lack of confirming ELISA positive test results using an immuno-blot test might lead to misinterpretation of anti-HCV false positive results as HCV exposures.

In conclusion, HIV-infected individuals had significantly higher positivity rate of anti-HCV although most of them had no sign of viraemia. Hence, with priority given for HIV-infected patients, testing those with anti-HCV for HCV-RNA is important in order to manage HIV-HCV co-infected patients appropriately. Further studies on the epidemiology of HCV infection in our settings are imperative to plan intervention methods systematically.

Acknowledgements
The authors would like to thank the counsellor nurses and laboratory personnel in Hawassa Referral Hospital for their kind assistance during data collection. We extend our appreciation to Dr. Tekalign Debalkie for valuable comments and Mrs Askale Tesfaye for laboratory works. We are also most grateful to the study subjects who demonstrated willingness to participate in the study.

We acknowledge the Government of Netherlands (Maastricht University) for considerable financial support, and the Aklilu Lemma Institute of Pathobiology, Addis Ababa University, and the International Clinical Laboratories for supplementary backing.

Author details
1Department of Medical Laboratory Science, Hawassa University, P. O. Box: 1560 Hawassa, Ethiopia. 
2Aklilu Lemma Institute of Pathobiology, Addis Ababa University, P. O. Box: 1176, Addis Ababa, Ethiopia.

Authors' contributions
All authors contributed to the study design, AA carried out data collection and laboratory works; AA and TS performed data analysis and interpretation; all authors contributed to final write up and approved the manuscript.

Competing interests
The authors declare that they have no competing interests.

Received: 14 February 2011 Accepted: 15 June 2011 Published: 15 June 2011

References
1. Lavanchy D: The global burden of hepatitis C. Liver Int 2009, 29:74-81.
2. Alter MJ: Epidemiology of hepatitis C virus infection. Gastroenterol 2007, 13:2436-2441.
3. Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH: Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med 2000, 132:296-305.
4. Alter MJ: Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 2006, 44:6-9.
5. Thimme R, Spangenberg H, Blum H: Hepatitis B or hepatitis C and human immunodeficiency virus infection. J Hepatol 2005, 42:37-44.
6. Frommel D, Tekle-Hamanzet R, Berhe N, Ausel L, Verdier M, Preux P, Denis F: A survey of antibodies to hepatitis C virus in Ethiopia. Am J Trop Hyg 1993, 49:435-439.
7. Ayele W, Nokes DJ, Abebe A, Messele T, Dejene A, Enquselassie F, Rinke de Wit FT, Fontanet LA: Higher prevalence of anti-HCV antibodies among HIV positive compared to HIV negative inhabitants of Addis Ababa, Ethiopia. J Med Virol 2002, 68:12-17.
8. Torso C, Simon A, Amor A, Lemere C, Res P, Soriano V: HCV seronegative infections in HIV patients with profound immunosuppression. Fourth International Workshop on HIV and Hepatitis Co-infection Madrid, Spain, 2008.
9. Buxton AJ, Yu A, Kim HP, Spinelli JJ, Kuo M, Alvarez M, Gilbert M, Krajden M: HCV coinfection in HIV positive population in British Columbia, Canada. BMC Public Health 2010, 10:225-236.
10. Rockstroh JK, Mocroft A, Soriano V, Tural C, Losso HA, Horban A, Kirk O, Phillips A, Ledergerber B, Lundgren J, for the EuroSIDA Study Group: Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis 2005, 192:992-1002.
11. Updated US Public Health Service guidelines for the management of occupational exposures to HBV, HCV and HIV and recommendations for postexposure prophylaxis. MMWR 2003, 50:1-42.
12. Ethiopian Public Health Association (EPHA): Identifying HIV/AIDS, sexually transmitted infections and tuberculosis research gaps and priority setting agenda in Ethiopia, 2005.
13. Brandão BMA, Fuchs CS: Risk factors for hepatitis C virus infection among blood donors in southern Brazil: a case-control study. BMC Gastroenterol 2002, 2:18-26.
14. Shev S, Widell A, Bergström T, Hermodsson S, Lindholm A, Norkrans G: Risk factors for HCV-RNA negativity among HCV-seropositive blood donors. J Hepatol 2006, 44:37-44.
15. Mohsen AH, Easterbrook P, Taylor CB, Norris S: Hepatitis C and HIV-1 coinfection. Gut 2002, 51:601-608.
16. Medhat A, Shehata M, Magder LS, Micknall N, Abdel-Baki L, Nafeh M, Abdel-Hamid M, Strickland GT: Ficaz AIDS. Ann Intern Med 2002, 136:633-638.
17. Wolff FH, Fuchs SC, Barcellos NNT, Ricardo de Alencastro P, Ikeda R ML, Hamid M, Strickland GT, Fix AD: Epidemiology of viral hepatitis and HIV co-infection. Gastroenterol 2002, 200:601-608.
18. Brandão BMA, Falcavigna M, Fuchs CS: Correlates of hepatitis C virus infection in HIV-infected patients in southern Brazil: genotype distribution and clinical correlates. PLoS ONE 2010, 5:e10049.
19. Orland J, Murphy LE, Wright JD, Kleinman S, for the NHLBI Retinovirus Epidemiology Donor Study (REDS) Group: Correlates of hepatitis C virus (HCV) RNA negativity among HCV-seropositive blood donors. Transfusion 2006, 46:469-475.
20. Thomas DL, Astemborski J, Rai RM, Anania FA, Schaeffer M, Galai N, Holt K, Nelson KE, Strathease SA, Johnson L, Layenenderke D, Baimott J, Wilson LE, Vlahov D: The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000, 284:450-456.
21. Shores NJ, Maida L, Soriano V, Núñez M: Sexual transmission is associated with spontaneous HCV clearance in HIV-infected patients. J Hepatol 2008, 49:323-328.

doi:10.1186/1756-0500-4-193

Cite this article as: Alemayehu et al.: Prevalence and risk factors of Hepatitis C among individuals presenting to HIV testing centers, Hawassa city, Southern Ethiopia. BMC Research Notes 2011 4:193.